Development of comprehensive disease assessment in systemic vasculitis. - Wikidata - awgldk - TriplyDB

Development of comprehensive disease assessment in systemic vasculitis.

Development of comprehensive disease assessment in systemic vasculitis.

http://www.wikidata.org/entity/Q35759939

about

Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials.Patient-reported outcome assessment in vasculitis may provide important data and a unique perspective Clinical Predictors of Outcome in Patients with Anti-neutrophil Cytoplasmic Autoantibody-related Renal Vasculitis: Experiences from a Single-center.Progress towards a core set of outcome measures in small-vessel vasculitis. Report from OMERACT 9.Outcome and treatment of elderly patients with ANCA-associated vasculitis.Unfavorably Altered Fibrin Clot Properties in Patients with Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome): Association with Thrombin Generation and Eosinophilia.Circulating Level of Neutrophil Extracellular Traps Is Not a Useful Biomarker for Assessing Disease Activity in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: the JMAAV study.Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index An approach to the diagnosis and management of systemic vasculitis.The pulmonary vasculitides.Damage assessment in ANCA-associated vasculitis.Efficacy and safety of sofosbuvir-based, interferon-free therapy : The Management of rheumatologic extrahepatic manifestations associated with chronic hepatitis C virus infection.Circulating neutrophil gelatinase-associated lipocalin: a useful biomarker for assessing disease activity of ANCA-associated vasculitis.Clinical value of systemic symptoms in IgA nephropathy with ANCA positivity.[S1 guidelines Diagnostics and treatment of ANCA-associated vasculitis].Risk factors for infectious complications of ANCA-associated vasculitis: a cohort study.

P2860

Q30849537-D507442C-306E-486A-BF6F-030590B2FFFE Q33607935-DE4BA8F3-F1B9-43BE-A3EB-DE1EEAC19732 Q33608983-9648A57F-F70D-47E8-8A2E-D5BEBF85CB93 Q35124613-E76D4E57-F68D-4EDD-B74A-55BA66F8C040 Q35816989-03AA83FE-4338-4E00-BC9D-80D206AC150A Q35833396-66E0EA55-DDF8-43C5-B15D-B079BC6C3BC3 Q35913208-F6AEA40A-6600-4E4F-B721-B6178E6206BC Q36032823-4F4DEFE1-E2AC-4DAE-A7A6-A6922EDCEEB6 Q37170449-53CAF465-FFB0-45B1-A339-012D952078C6 Q37673239-76BBEAC5-C1C6-41A7-8D50-FCE1CD5D2D9B Q38017164-402AC147-63BF-4E45-BC4F-F246C333649C Q38043946-2E0286B2-1AFA-4A9E-A489-04947F637A72 Q40088333-4C25A4D7-DB36-49C5-A7D5-3690DEE118AC Q46139426-F748370D-AD12-4F83-A037-6744C524C700 Q47587352-3B53FDFC-8D76-4034-8967-8C6FD4C07A72 Q50076914-949C8EBD-AC06-4BF8-A59B-DB68BE2C4DDC Q55440952-07F99806-49AA-45F5-9D78-EBC9354260C3

P2860

Development of comprehensive disease assessment in systemic vasculitis.

http://www.wikidata.org/entity/Q35759939

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Development of comprehensive disease assessment in systemic vasculitis.

@ast

Development of comprehensive disease assessment in systemic vasculitis.

@en

type

label

Development of comprehensive disease assessment in systemic vasculitis.

@ast

Development of comprehensive disease assessment in systemic vasculitis.

@en

prefLabel

Development of comprehensive disease assessment in systemic vasculitis.

@ast

Development of comprehensive disease assessment in systemic vasculitis.

@en

P1433

Q35759939-5D03888C-ED9A-4E5A-92C8-0AA1BC3324DD

P1476

Q35759939-170D8318-6D68-47EE-8AC4-F4B8980E11AD

P2093

Q35759939-10C9F3F6-3B69-4B73-A332-AA27348BFA78

Q35759939-48CAB207-1C83-4D22-B305-60E0F7ACC98C

Q35759939-78C5FBD1-1A75-4FBD-8705-AC73CA39ED8B

Q35759939-794894D0-D8FF-48DA-8ABD-BAD21DF619A7

Q35759939-D5425420-77F5-4C12-BE9B-5383680AF6A2

Q35759939-D622519B-E03B-40C5-9346-E78BFD3E7696

Q35759939-E96C36A4-38F6-49AA-9FCA-253CBAD7CB83

Q35759939-FD469DEC-42C7-4FC3-98CC-7939C68B904F

P2860

Q35759939-047BBB9D-D451-469B-BB36-1A929A3191AE

Q35759939-0F41EE72-9D80-44E0-8F82-24BDF9FB7D2B

Q35759939-12919489-F15E-4F42-BB99-DA0B2193031D

Q35759939-1EBBDFCC-DDE0-452C-847F-3DD17D5019E7

Q35759939-28CD9672-8CDA-4113-97A2-931193BD9DFC

Q35759939-2A31E60A-CFAD-4067-9D4C-BBC9DC9A8CBF

Q35759939-2D804099-ACC1-460E-A832-8A6519B1A7FA

Q35759939-31C6A722-9AEA-4439-9E11-634E4713533B

Q35759939-31EEEFFA-7ED0-42EA-806F-A0BEA5576EEB

Q35759939-3DDE4611-D50A-46A6-955B-B79FB1717900

P304

Q35759939-7ABC5500-4813-4839-AE3B-3421E710A735

P31

Q35759939-EB2A731D-893A-450F-8BBD-F576862D1FC4

Q35759939-bc4c44d0-a741-4fba-b7b2-1bdb7735ae1d

P356

Q35759939-A003A681-2DF1-4E59-8E8B-F4D07C96A7B2

P407

Q35759939-ED73CFE8-117A-4DBF-85BC-364FBB2520CD

P433

Q35759939-5E72E0A0-3BF1-472C-A7AA-95C36B986E45

P478

Q35759939-6F4AF66D-A483-4817-BCD6-7F5EFD850294

P577

Q35759939-DA523C14-1A34-4A68-A4DB-97CB3DFE5635

P698

Q35759939-3EE23872-D18A-4EF4-99CD-2A06D5F2F1B7

Q35759939-f293afc2-3864-4070-972d-0cb215682123

P932

Q35759939-C9E87779-8E7E-48D2-9BD8-907F377E093D

P356

ARD.2005.051078

P1433

Annals of the Rheumatic Diseases

P1476

Development of comprehensive disease assessment in systemic vasculitis.

@en

P2093

David Jayne

http://www.w3.org/2001/XMLSchema#string

Kerstin Westman

http://www.w3.org/2001/XMLSchema#string

Kirsten de Groot

http://www.w3.org/2001/XMLSchema#string

Niels Rasmussen

http://www.w3.org/2001/XMLSchema#string

Oliver Flossmann

http://www.w3.org/2001/XMLSchema#string

Paul Bacon

http://www.w3.org/2001/XMLSchema#string

Philip Seo

http://www.w3.org/2001/XMLSchema#string

Raashid Luqmani

http://www.w3.org/2001/XMLSchema#string

P2860

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

Nomenclature of systemic vasculitides. Proposal of an international consensus conference

Outcome measures and classification criteria for the rheumatic diseases. A compilation of data from OMERACT (Outcome Measures for Arthritis Clinical Trials), ILAR (International League of Associations for Rheumatology), regional leagues and other gr

Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET).

The socioeconomic impact of vasculitis.

Etanercept plus standard therapy for Wegener's granulomatosis.

Update on the European Vasculitis Study Group trials.

Prognosis and outcome of 26 patients with systemic necrotizing vasculitis admitted to the intensive care unit.

The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis.

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

P304

283-292

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ARD.2005.051078

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P577

2006-05-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16728460

http://www.w3.org/2001/XMLSchema#string

P932

1855994

http://www.w3.org/2001/XMLSchema#string